Last €0.39 EUR
Change Today 0.00 / 0.00%
Volume 0.0
TN7 On Other Exchanges
As of 2:56 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

titan pharmaceuticals inc (TN7) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/8/14 - €0.63
52 Week Low
11/19/14 - €0.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

titan pharmaceuticals inc (TN7) Related Businessweek News

No Related Businessweek News Found

titan pharmaceuticals inc (TN7) Details

Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company’s lead product candidate is Probuphine, a slow release implant formulation of buprenorphine in development for the long term maintenance treatment of opioid dependence. Its Probuphine is designed to maintain a stable and around the clock blood level of the medicine in patients for six months following a single treatment and utilizes ProNeura, a novel, proprietary, and long-term drug delivery technology. The company’s ProNeura is also used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease. Its products also comprise Fanapt (iloperidone), an atypical antipsychotic for the treatment of schizophrenia. The company was founded in 1992 and is based in South San Francisco, California.

13 Employees
Last Reported Date: 10/3/14
Founded in 1992

titan pharmaceuticals inc (TN7) Top Compensated Officers

Principal Executive Officer, President, Princ...
Total Annual Compensation: $300.0K
Executive Chairman and Member of Executive Co...
Total Annual Compensation: $210.0K
Compensation as of Fiscal Year 2013.

titan pharmaceuticals inc (TN7) Key Developments

Titan Pharmaceuticals Inc. Presents at LD Micro Conference, Dec-04-2014 08:30 AM

Titan Pharmaceuticals Inc. Presents at LD Micro Conference, Dec-04-2014 08:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States. Speakers: Sunil Bhonsle, Principal Executive Officer, President, Principal Financial Officer, Secretary and Director.

Titan Pharmaceuticals Inc. Announces Completion of Enrollment in Phase 3 Study of Probuphine for Opioid Dependence

Titan Pharmaceuticals Inc. announced completion of enrollment in the ongoing Phase 3 study of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. Study completion is expected to be on schedule by the middle of 2015, paving the way for resubmission of the New Drug Application (NDA) for Probuphine with the U.S. Food and Drug Administration (FDA) later in the year. The study, which is being sponsored and managed by Braeburn Pharmaceuticals, has randomized 178 patients across 21 centers. With a low screening failure rate and high patient interest, Braeburn successfully enrolled the entire study in a little over four months. The Probuphine clinical study in progress is a randomized, double-blind, double-dummy design that has enrolled patients in two parallel treatment arms. The study population is clinically stable patients who are receiving maintenance treatment with an FDA-approved sublingual formulation containing buprenorphine at a daily dose of 8mg or less. Patients have been randomized either to receive four Probuphine implants or to continue the daily sublingual buprenorphine therapy. The patients are expected to be treated for six months, and the primary analysis will be a non-inferiority comparison of responders in the two arms.

Titan Pharmaceuticals Inc. Reports Unaudited Earnings Results Third Quarter and Nine Months Ended September 30, 2014

Titan Pharmaceuticals Inc. reported unaudited earnings results third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue was $911,000 against $2,198,000 a year ago. Loss from operations was $738,000 against $128,000 a year ago. Net income and comprehensive income was $716,000 against loss of $1,145,000 a year ago. Diluted loss per share was $0.01 against loss of $0.01 per basic share a year ago. Revenue earned during the quarters ended Sept. 30, 2014 and 2013 reflects the amortization of the upfront license fee received from development and commercialization partner Braeburn Pharmaceuticals in December 2012. For the nine months, the company reported total revenue was $2,734,000 against $9,570,000 a year ago. Loss from operations was $2,222,000 against $249,000 a year ago. Net loss and comprehensive loss was $1,930,000 against income of $9,920,000 a year ago. Diluted loss per share was $0.03 against earnings of $0.11 per share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TN7:GR €0.39 EUR 0.00

TN7 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $58.80 USD -0.08
Reckitt Benckiser Group PLC 5,310 GBp +30.00
View Industry Companies

Industry Analysis


Industry Average

Valuation TN7 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.5x
Price/Book 12.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TITAN PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at